Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $56.8 million.

  • Outlook Therapeutics' Total Liabilities fell 1561.52% to $56.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $56.8 million, marking a year-over-year decrease of 1561.52%. This contributed to the annual value of $50.8 million for FY2025, which is N/A changed from last year.
  • Per Outlook Therapeutics' latest filing, its Total Liabilities stood at $56.8 million for Q4 2025, which was down 1561.52% from $50.8 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Total Liabilities ranged from a high of $67.3 million in Q4 2024 and a low of $50.8 million during Q3 2025